Last reviewed · How we verify
Dupilumab - Discontinuation
At a glance
| Generic name | Dupilumab - Discontinuation |
|---|---|
| Also known as | Dupixent |
| Sponsor | Johns Hopkins University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (PHASE3)
- Dupilumab De-escalation in Pediatric Atopic Dermatitis (PHASE4)
- Complete Remission After Treatment With Biologics for Nasal Polyps (PHASE4)
- Withdrawal of Dupilumab in Severe Asthma (PHASE4)
- Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
- Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors (NA)
- Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) (PHASE3)
- Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dupilumab - Discontinuation CI brief — competitive landscape report
- Dupilumab - Discontinuation updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI